Mar 23, 2021 / 12:00PM GMT
Operator
Good morning, everyone, and welcome to Zealand Pharma's conference call to discuss the U.S. FDA's approval of Zegalogue for the treatment of severe hypoglycemia. (Operator Instructions) Today's call is being recorded.
At this time, I would now like to turn the call over to Matt Dallas, Senior Vice President, Chief Financial Officer. Matt?
Matthew Donald Dallas - Zealand Pharma A/S-Senior VP&CFO
Thank you, operator. Welcome, and thank you for joining us today to discuss Zealand's U.S. FDA approval of Zegalogue. I'm Matt Dallas, Senior Vice President and Chief Financial Officer of Zealand. With me today are Zealand's President and Chief Executive Officer, Emmanuel Dulac; Chief Medical Officer, Adam Steensberg; and Frank Sanders, our President of the U.S. -- Zealand Pharma U.S. The team will respectively provide an overview of the approval of Zegalogue label and indication data and the commercialization strategy. After the prepared remarks, we will open the call to take your questions. You can find the
Zealand Pharma A/S Corporate Call Transcript
Feb 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers